SCHEMBL2628027

SCHEMBL2628027

NCC(CCOCc1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.47
TSHR P16473 1/20 0.47
GABBR2 O75899 2/20 0.45
GABBR1 Q9UBS5 2/20 0.45
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MPO P05164 1/20 0.43
TPO P07202 1/20 0.43
CYP3A4 P08684 1/20 0.43
HTR2A P28223 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA4 P43681 1/20 0.41
IDO1 P14902 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2628023 0.85 IDO1 (0.42) TACR1HTTSMN1; SMN2MPOTPO
SCHEMBL1879700 0.82 TACR1 (0.59) TACR1TSHRGABBR2GABBR1HTR2A
Hydrochloric Acid SCHEMBL1874510 0.81 TACR1 (0.57) TACR1TSHRGABBR2GABBR1
SCHEMBL7964372 0.79 TSHR (0.50) TACR1TSHRHTTSMN1; SMN2MPO
SCHEMBL3580534 0.79 TSHR (0.50) TACR1TSHRHTTSMN1; SMN2MPO
SCHEMBL20207392 0.77 TSHR (0.48) TACR1TSHRHTTSMN1; SMN2MPO
SCHEMBL20177696 0.77 TSHR (0.48) TACR1TSHRHTTSMN1; SMN2MPO
SCHEMBL22870057 0.77 CA1 (0.50) TACR1TSHRHTTSMN1; SMN2IDO1
SCHEMBL2633195 0.77 HTR2A (0.42) TSHRGABBR2GABBR1HTR2ATAAR1
SCHEMBL28214514 0.76 TSHR (0.40) TACR1TSHRHTTSMN1; SMN2MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357809-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-22 US disclosed
US-20120094983-A1 ACYCLIC IKUR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-19 US disclosed
US-7915410-B2 Acyclic IKur inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-29 US disclosed
US-20070082909-A1 Acyclic Ikur inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082909-A1 Acyclic Ikur inhibitors KCNH2, KCNJ2, KCNH3 TACR1 382/4885TSHR 566/4885GABBR2 1126/4885
US-20120094983-A1 ACYCLIC IKUR INHIBITORS KCNH2, KCNJ2, KCNH3 TACR1 382/4885TSHR 566/4885GABBR2 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.